LRP and P-Glycoprotein (P-gp) Status in Relation to Outcome of Induction Chemotherapy
| . | No. of Patients . | Complete Remission . | Resistant Disease . | Early Death . | Not Evaluable . |
|---|---|---|---|---|---|
| Total | 82 | 59 (72%) | 9 (11%) | 10 (12%) | 4 (5%) |
| LRP−/P-gp− | 49 | 41 (84%) | 4 (8%) | 3 (6%) | 1 (2%) |
| LRP+/P-gp−or LRP−/P-gp+ | 28 | 16 (57%) | 3 (11%) | 6 (21%) | 3 (11%) |
| LRP+/P-gp+ | 5 | 2 (40%) | 2 (40%) | 1 (20%) | 0 (0%) |
| . | No. of Patients . | Complete Remission . | Resistant Disease . | Early Death . | Not Evaluable . |
|---|---|---|---|---|---|
| Total | 82 | 59 (72%) | 9 (11%) | 10 (12%) | 4 (5%) |
| LRP−/P-gp− | 49 | 41 (84%) | 4 (8%) | 3 (6%) | 1 (2%) |
| LRP+/P-gp−or LRP−/P-gp+ | 28 | 16 (57%) | 3 (11%) | 6 (21%) | 3 (11%) |
| LRP+/P-gp+ | 5 | 2 (40%) | 2 (40%) | 1 (20%) | 0 (0%) |
LRP and P-gp expression of leukemic blasts was determined as described in Patients and Methods. Induction chemotherapy included MDR drugs (daunorubicin, etoposide) in most patients. Response to induction chemotherapy was assessed according to standard criteria. Response data are shown for patients without expression of these two genes, for patients with expression of either of these genes, and for patients with expression of both genes. Statistical analysis (chi-squared test) for complete remission: P = .004.